View
1
Download
0
Category
Preview:
Citation preview
ABSTRACTOrganicmoleculeshavebiologicalactivityforavarietyofstructuralfeatures,someactivitiesareassociatedwiththestructural basis of a known molecule, and others are associated with the type and orientation of additive modifications. However, acetylcholine (ACh) is the main neurotransmitter of the parasympathetic nervous system, the part of the autonomic nervous system that contracts smooth muscles, dilates blood vessels, increases body secretion, and slows the heartrate.Inthecentralnervoussystem,AChhasseveralrulesanditplaysanimportantroleinmemoryandlearning,aswellas,inthe abnormal deficiency of ACh in the brain in people with Alzheimer’s disease. In the past, it has been attempted to use ACh chlorideascholinergicstimulants,but,unfortunately,ithasbeenfoundthatitdoesnothavealastingeffectbecauseofitstoo short action duration due to its rapid hydrolysis by acetylcholinesterase (AChE) enzymes and the lack ofspecificity.Keywords: Choline, Modification, Choline Esterase, Choline Acetyltransferase, Alzheimer disease, EDTA chelating agent. International Journal of Pharmaceutical Quality Assurance (2020); DOI: 10.25258/ijpqa.11.3.10How to cite this article: Abramovich RA, Potanina OG, Al-Shareeda ZA, Alhejoj HM. Modification of choline derivatives andthestudyoftheirpharmacologicalactivity.InternationalJournalofPharmaceuticalQualityAssurance.2020;11(3):1-12. Source of support: Nil.Conflict of interest: None
Modification of Choline Derivatives and the Study of their Pharmacological Activity
Zinah. A. Al-shareeda1, R. A. Abramovich2, O. G. Potanina3, Hassan M. Alhejoj4
1Postgraduate Student of the Department of Pharmaceutical Chemistry and Pharmacognosy of the Center for Collective Use (SEC) of the RUDN University.
2Director of the Center for Collective Use (Scientific and Educational Center) of RUDN. Doctor of PharmaceuticalSciences, Associate Professor, Head of the Department of Technology for Preparation of Medicines and Organization of Pharmaceutical Business, Faculty of Advanced Training of Medical Workers, Peoples’ Friendship University of Russia.
3Director of the Center for Scientific Research and Development of the Center for Collective Use (SEC) of the RUDN University, Dr. sciences. Head of the Department of Pharmaceutical Chemistry and Pharmacognosy, Center for Collective
Use (SEC), RUDN.4PHD. biology and general genetics. Assistant of the Department of Public Health, Healthcare and Hygiene.
Received: 18th June, 2020; Revised: 04th July, 2020; Accepted: 16th August, 2020; Available Online: 25th September, 2020
INTRODUCTIONBrain chemical ACh plays a very necessary role in methods of regulating human body structure, which is related to the study of body functions. This does not serve the development of agents that imitate the effect of ACh, as well as, those which block the effect of ACh as medically supporting agents. Scientists are getting better information from these developments about treating special diseases, like brain disease, Parkinson’s disease, and urine storage sac (bladder).
For professional pharmacists, it is important to know how the autonomic nervous system influences usual body structure related to function and how they can be targeted in controlling sicknesses. Dale1 explained the actions of esters and ethers of choline on organs and their relationship to muscarine. Since then, the medical drug experts, physiologists, chemists, and scientists who study the chemicals in living things,
RESEARCH ARTICLE
have used the knowledge gained to know the actions of the cholinergic nerve and its brain chemical.
Loewi first found ACh in frog heart in the year 1921. It was found as a substance released by vagus nerve stimulation. At that time, the complex difficulty of action of ACh on cholinergic nerve cells and receptors was unknown. Subsequently, the advancement in the application of biotechnology and chemistry developed probes that uncovered this difficulty.2Cholinergic nerves are found in the peripheral nervous system and central nervous system (CNS) of humans. Investigators are releasing the mystery that surrounds thinking-related damage, especially, Alzheimer’s disease. Synaptic terminals in the brain, corpus striatum, hippocampus, and a few other areas in the CNS are rich in ACh and in the enzymes that create and break down this brain chemical. Multiple experiments have shown that agonists and antagonists of cholinergic receptors change output of brain chemicals, including ACh,
*Author for Correspondence: habibbaty@gmail.com
Modification of Choline Derivatives and the Study of their Pharmacological Activity
IJPQA, Volume 11 Issue 3 July 2020 – September 2020 Page 362
from brain preparations. In spite of the unobvious function of ACh in the brain, it is known that it is involved in memory and behavioral activity in humans.3 ACh receptors are classified into two types, viz., nicotinic and muscarinic. They have a different composition, location, and pharmacological action. Nicotine and muscarine, respectively, are the naturally occurring alkaloids that bind the nicotinic and muscarinic ACh receptors that has led to the said classification. There is a sub-classification for the receptors, on the basis of the differences in the location and the specification for the identified agonists and antagonists of nicotinic and muscarinic ACh receptors.
When ACh binds to the nicotinic receptor, it will lead to the change in permeability of the membrane allowing the cations Ca2-, Na-, and K- to pass through it. This will help the depolarization of the endplate, which will lead to the contraction of the muscle at the neuromuscular junction or, as occurs in autonomic ganglia, a continuation of the nerve impulse. It is important to know that the neuromuscular nicotinic ACh receptors can be used in surgical operations because of their autoimmune antibodies in myasthenia gravis and muscle relaxants. Some drugs block the nicotinic receptors which can help to control hypertension.
In 1980, it had appeared that the action of ACh could not be settled by one muscarinic receptor, that is why more studies were taken in 1980 to improve the usefulness of these receptors to be used as a target to treat many diseases that became predominant especially in elderly people. The functions of the cholinergic neurons are to synthesize, store, and release ACh. The other function of these neurons is the formation of two other enzymes, which are called choline acetyltransferase (ChAT) and AChE. They are produced in the soma of the neuron and distributed throughout the neuron by the axoplasmic flow. The location of AChE is outside the neuron and it is connected with the neuroglial cells in the synaptic cleft. In the nerve ending occurs the preparation of Ach, which takes a place by transporting an acetyl group from acetyl-coenzyme A (CoA) to choline with the help of the enzyme choline acetyltransferase. The latter enzyme plays an important role in the synthesis of ACh. The enzyme and the neurotransmitter are present in the cholinergic neurons,1-31 as well as, in some non-nervous tissues.1,2,4,5 Their function is unknown in the non-nervous tissues. On the other hand, the choline esterase (ChAc) is considered as a special marker for cholinergic neurons.
In order to study the characteristic features of this enzyme at the molecular level and to localize it in cholinergic cells by immune histochemical methods, with a precondition that this enzyme should have high purification. From the enzyme properties and the localization, it will help to clarify the cholinergic transmission mechanism, as well as, the allocation of the cholinergic neurons in the nervous system.32 Most of the choline which is needed for ACh synthesis comes from the breakdown of ACh in the synapses and then the choline will be regained again with the help of the sodium ions in the presynaptic terminal to synthesize ACh.25
AChE is the enzyme that is responsible for the breakdown of ACh. AChE is a type-B carboxylesterase enzyme which
is primarily located in the synaptic cleft with a smaller concentration in the extra junctional area. It is secreted by the muscle and stays attached by collagen. 50% of released ACh because of this enzyme is broke down into choline and acetate in a very short time (in less than 1 ms). Then, again the liberated choline will be used for the production of ACh in the nerve terminal. AChE has a high specific activity, which functions at a rate, which is near to that of a diffusion-controlled reaction.33 The powerful acute toxicity of organophosphorus (OP) poisons is the generation of drugs for the treatment of Alzheimer’s disease.34 AChE contains two subsites, viz., “esteratic” and “anionic.”35-37
It is important that the neuronal activity in the peripheral and central nervous systems is potently regulated by ACh.38,39
However, the clearly stated/particular (things that are given/ work that is done) of cholinergic neuromodulation to circuit function in the healthy brain and in psychiatric illness have been very hard to cut apart, due to its pleiotropic actions on nerve-related excitability, synaptic transmission, and network patterns (of relationships, movement, or sound). Recently, clever inventions in the field of molecular (the study of tiny chemical assembly instructions inside of living things), (body structure/ related to the study of body functions), and human imaging has opened up new dimensions to understand the circuits and behavior of neuromodulation shapes. Here, we discuss the progress in the field of cholinergic signaling that is added/given to the circuits which are involved in major depressive sickness/problem (MDD), the two groups of the psychiatric sicknesses/problems, and very serious mental disorder. Technical innovation will be given further stimulus to support the treatment of psychiatric diseases.
It is important to know that the abnormalities in the cholinergic system may lead to multiple diseases, for example, myasthenia gravis.40,41 This may also lead to other diseases, like Alzheimer’s and Parkinson’s disease.42,43 Recent researches are related to the dysfunction in the cholinergic system and the important role it plays in diseases, like schizophrenia and depression.
AIM OF THE STUDYModification of choline ester derivatives and the study of the pharmacological activity to counteract the problems of rapid hydrolysis and short duration of action of acetylcholine.
PHARMACOLOGICAL ACTIVITY OF ACH IN SCHIZOPHRENIA AND ATTENTIONThe symptoms of schizophrenia can be divided into two types, viz., positive and negative. Positive symptoms are disordered thoughts, delusions, and hallucinations. While, the negative symptoms are blunted affect and social withdrawal.44 It has been known that the brain chemicals, like serotonin and dopamine, in addition to Ach, lead to the contribution of this disease. Stimulation of the cholinergic nerve cells in the basal forebrain ontogenetically improved the visual performance in the mouse cortex.45 In spite of many years of continuous
Modification of Choline Derivatives and the Study of their Pharmacological Activity
IJPQA, Volume 11 Issue 3 July 2020 – September 2020 Page 363
working to understand the role of Ach, which is considered as evasive, in new studies which are related to human imaging gave a spot on the contribution of the cholinergic system in behavior. So, it is important to know that in order to treat neuropsychiatric diseases drugs should be directed to a targeted receptor subtypes and cell classes.
Researches must be directed forward to assure the link between the clinical and preclinical researches. To have a proper health and a good well being it is important to take choline which can be taken from the diet.46 Many diets contain this substance which is quite enough for health maintenance. The US Department of Agriculture website showed which types of food contain choline, i.e., free choline, glycerophosphocholine, phosphocholine, phosphatidylcholine, sphingomyelin, and betaine—a metabolite of choline.47 Adequate intake (AI) recommendations, issued by the Food and Nutrition Board of the Institute of Medicine of the National Academy of Sciences, which they said that 7.5 mg per kg of body weight is enough for a normal person,46 but the quantities increase in special cases like pregnancy and lactation to meet the requirements of the fetus and babies.48-50 Lower choline intake may lead to a lot of disorders, for example, liver dysfunction and other disorders,51-53 and vice versa high intakes help to reduce the risk of some cancers.54-58 Whether it is choline or its related metabolites which are considered as quaternary amine and they are very important in the structure of cell membranes, metabolism of methyl, neurotransmission, etc., this amine is widely distributed in tissues as phosphatidylcholine and sphingomyelin. There are a lot of studies that investigate the choline function and metabolism.59-61
On the contrary, there are a lot of studies that make sure that there is a link between the cholinergic activity and the normal behaviors ruptured in patients with schizophrenia. When ACh is applied locally it gives a great push in the improvement of neuronal activity in the primary visual cortex leading to increase attention. While other drugs that reverse the action which is called antagonists, like scopolamine, reduce attention.44 Because of the short duration of action of ACh due to its hydrolysis by a certain enzyme which is called AChE, and due to the importance of this neurotransmitter for the treatment of many neuronal diseases, this point gave an orientation to look forward to improving ways to get all the benefits of this neurotransmitter in treating many diseases depending on it.
PHARMACOLOGICAL CHARACTERISTICS OF CHOLINE ESTERSCholine esters may be defined as a modified compound of choline which is used nowadays clinically. For example, according to a study done by Williams,62 this study was considered as a patent this study summarized that all people when they become elderly they will suffer from presbyopia and cataract, which are age-related diseases, they are normally treated by using corrective lenses if treatment is not found.
A new formulation was done to reduce the risk of toxicity of the surrounding healthy tissues this formulation, which is formulated as an eye drop that consists of 0.25 to about 10%
of a reducing agent that is choline ester it has been found that this eye drop ensures ocular delivery. Another study showed the use of choline esters to enhance the absorption of the drug by many other routes (nasal, buccal, vaginal, and sublingual) and to avoid the first-pass metabolism when given orally and this help to ensure drug stability in spite the oral route is one of the proffered routs but not all the drugs have good absorption so from here the idea started of choline esters to promote absorption and also it is proved that they may not necessarily segregate divalent cations (Mg---- or Ca++) which are important for cell function. This gives an advantage over the chelating agent Ethylenediaminetetraacetic acid (EDTA). . It means with choline esters no damage of the tissue occurred according to many studies as compared with a surfactant activity (sodium lauryl sulfate).
Another patent was done by Jose A.63; this study was done for drugs with low bioavailability because of poor absorption so they were administrated with choline esters in a special form suitable for oral or rectal delivery. Another patent64 was done to make a low choline odor of an organic compound, like choline ellagate to help with the delivery. Choline deficiency occurs in men and post-menopausal women with a low-calorie diet. Sometimes choline is used to support the delivery and uptake of the nutrients to reach the daily recommended dose for example in fortified food.
STANDARDS OF CHOLINE AND CHOLINE ESTERS IN USP, EP, AND RUSSIAN PHARMACOPEIA92-94
USP Reference Standards
Choline Bitartrate
C9H19NO7 253.252-hydroxyethanaminium,-N,N,N-trimethyl, [R-(R*,R*)]-
2,3-dihydroxybutanedioate (1:1)(2-hydroxyethyl) trimethylammonium-L-(+)-tartrate
salt (1:1) [87-67-2]• Choline bitartrate contains not less than 99 percent and
not more than 100.5 percent of C9H19NO7, calculated on the anhydrous basis.
Identification:A: Infrared absorption <197K>.B: Dissolve 1-gram of choline bitartrate with 20 mL of water, and add 2 mL of potassium chloride solution (1 in 4). A white precipitate of potassium bitartrate is formed.Specific rotation <781S>: between + 17.5 and + 18.5º.Test solution: 400 mg per mL, in water.pH <791>: between 3 and 4, in a solution (1 in 10).Water, method I <921>: Not more than 0.5%.Residue on ignition <281>: Not more than 0.1%.
Modification of Choline Derivatives and the Study of their Pharmacological Activity
IJPQA, Volume 11 Issue 3 July 2020 – September 2020 Page 364
Tabl
e 1:
Cho
line
este
r pre
para
tions
whi
ch a
re re
gist
ered
in th
e St
ate
Reg
iste
r of M
edic
ines
92
No.
p
/ p
Trad
e na
me
Inte
rnat
iona
l no
npro
prie
tary
na
me
or g
roup
ing
(che
mic
al) n
ame
Rele
ase
form
Nam
e of
hol
der
or h
olde
r of d
rug
regi
stra
tion
cert
ifica
te
Cou
ntry
of
hol
der
or h
olde
r of
dru
g re
gist
ratio
n ce
rtifi
cate
Regi
stra
tion
num
ber
Stat
e re
gistr
atio
n da
te
Expi
ratio
n da
te re
g.
beat
s
Re-
regi
stra
tion
date
of R
UC
ondi
tion
Dec
isio
n da
te
1H
oly
Alp
haC
holin
e al
fosc
erat
e
solu
tion
for
infu
sion
and
in
tram
uscu
lar
inje
ctio
n;
Lim
ited
Liab
ility
C
ompa
ny “
Velfa
rm”
(LLC
“Ve
lfarm
”)R
ussi
aLP
-005
108
10/1
5/20
1810
/15/
2023
12/1
0/20
18D
12/1
0/20
18
2A
lfokh
olin
-Le
kfar
mC
holin
e al
fosc
erat
e
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
Join
t lim
ited
liabi
lity
com
pany
“L
ekph
arm
” (J
LLC
“L
ekph
arm
”)
Rep
ublic
of
Bel
arus
LP-0
0486
905
/29/
2018
05/2
9/20
23-
D09
/06/
2019
3C
eret
on®
Cho
line
alfo
scer
ate
oral
solu
tion;
Clo
sed
Join
t-Sto
ck
Com
pany
Far
mFi
rma
Sote
ks (C
JSC
Ph
arm
Firm
a So
teks
)
Rus
sia
LP-0
0482
904
/26/
2018
04/2
6/20
23-
D04
/26/
2018
4C
holin
e al
fosc
erat
eC
holin
e al
fosc
erat
eor
al so
lutio
n;
Clo
sed
Join
t-Sto
ck
Com
pany
Ber
ezov
sky
Phar
mac
eutic
al
Plan
t (C
JSC
BFZ
)
Rus
sia
LP-0
0477
704
/03/
2018
04/0
3/20
23-
D04
/03/
2018
5C
holin
e al
fosc
erat
eC
holin
e al
fosc
erat
e
solu
tion
for
infu
sion
and
in
tram
uscu
lar
inje
ctio
n;
PJSC
“B
iosy
nthe
sis”
Rus
sia
LP-0
0475
303
/26/
2018
03/2
6/20
23-
D03
/26/
2018
6C
holin
e al
fosc
erat
eC
holin
e al
fosc
erat
e
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
Ato
ll Li
mite
d Li
abili
ty
Com
pany
(Ato
ll LL
C)
Rus
sia
LP-0
0381
608
/31/
2016
08/3
1/20
2109
/26/
2019
D09
/26/
2019
7C
holin
e al
fosc
erat
eC
holin
e al
fosc
erat
e
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion,
25
0 m
g / m
L (a
mpo
ule)
4
mL
x 3/
5 (p
ack
of c
ardb
oard
)
Farm
Inte
llect
Lim
ited
Liab
ility
Com
pany
(P
harm
Inte
llect
LLC
)R
ussi
aLP
-003
771
08/1
0/20
1608
/10/
2021
07/2
5/20
19D
-
8C
holin
e al
fosc
erat
eC
holin
e al
fosc
erat
e
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
Ope
n Jo
int-S
tock
C
ompa
ny “
Bor
isov
Pl
ant o
f Med
ical
Pr
epar
atio
ns”
(OJS
C
“BZM
P”)
Rep
ublic
of
Bel
arus
LP-0
0376
808
/08/
2016
08/0
8/20
2108
/10/
2018
D08
/10/
2018 C
ont..
.
Modification of Choline Derivatives and the Study of their Pharmacological Activity
IJPQA, Volume 11 Issue 3 July 2020 – September 2020 Page 365
9C
holin
e al
fosc
erat
eC
holin
e al
fosc
erat
e
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
Ella
ra L
imite
d Li
abili
ty
Com
pany
(Ella
ra
LLC
)
Rus
sia
LP-0
0324
110
/08/
2015
10/0
8/20
2010
/10/
2017
D07
/30/
2019
10N
oopr
in®
Cho
line
alfo
scer
ate
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
Join
t-sto
ck c
ompa
ny
“Nov
osib
khim
phar
m”
(JSC
“N
ovos
ibkh
imph
arm
”)
Rus
sia
LP-0
0324
310
/08/
2015
10/0
8/20
2008
/09/
2018
D08
/14/
2019
11G
liatil
inC
holin
e al
fosc
erat
e
solu
tion
for
infu
sion
and
in
tram
uscu
lar
inje
ctio
n;
Italfa
rmak
o S.
p.A
.Ita
lyLP
-003
090
07/1
4/20
1507
/14/
2020
-D
12/1
0/20
18
12C
holin
e al
fosc
erat
eC
holin
e al
fosc
erat
e
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
Ope
n Jo
int-
Stoc
k C
ompa
ny
Kur
gan
Join
t-St
ock
Com
pany
of
Med
ical
Pre
para
tions
an
d Pr
oduc
ts
“Syn
thes
is”
(OJS
C
“Syn
thes
is”)
Rus
sia
LP-0
0252
207
/04/
2014
-07
/05/
2019
D07
/05/
2019
13D
elec
itis
Cho
line
alfo
scer
ate
solu
tion
for
infu
sion
and
in
tram
uscu
lar
inje
ctio
n;
LLC
“IT
F”R
ussi
aLP
-001
577
03/0
7/20
12-
08/1
0/20
17D
08/1
0/20
17
14G
liatil
inC
holin
e al
fosc
erat
eor
al so
lutio
n;Ita
lfarm
ako
S.p.
A.
Italy
LP-0
0154
002
/27/
2012
-06
/28/
2017
D12
/11/
2018
15D
elec
itis
Cho
line
alfo
scer
ate
caps
ules
;LL
C “
ITF”
Rus
sia
LP-0
0153
602
/27/
2012
-09
/06/
2017
D09
/06/
2017
16-
Cho
line
alfo
scer
ate
Cho
line
alfo
scer
ate
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
Lim
ited
liabi
lity
com
pany
“C
OM
PAN
Y”
DEC
O
“(LL
C”
CO
MPA
NY
“D
ECO
”)
Rus
sia
LP-0
0143
101
/12/
2012
-10
/07/
2019
D10
/07/
2019
17O
tinum
Cho
line
Salic
ylat
eea
r dro
ps;
Med
a Ph
arm
a gm
bH
and
Co.
KG
Ger
man
yP
N01
1858
/ 0
111
/22/
2011
-07
/02/
2014
D10
/02/
2019
18N
ooch
olin
R
omph
arm
Cho
line
alfo
scer
ate
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
K.O
. Rom
phar
m
Com
pany
S.R
.L.
Rom
ania
LP-0
0071
509
/29/
2011
-10
/06/
2016
D09
/06/
2019
19C
eret
on®
Cho
line
alfo
scer
ate
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
Clo
sed
Join
t-Sto
ck
Com
pany
Far
mFi
rma
Sote
ks (C
JSC
Ph
arm
Firm
a So
teks
)
Rus
sia
LS-0
0265
209
/21/
2011
--
D07
/29/
2019
20H
olis
al®
Cho
line
Salic
ylat
e +
Cet
alko
nium
C
hlor
ide
dent
al g
el;
LLC
“VA
LAN
TE”
Rus
sia
P N
0121
18
/ 01
08/2
4/20
10-
04/1
4/20
14D
09/2
7/20
19
Con
t...
Con
t...
Modification of Choline Derivatives and the Study of their Pharmacological Activity
IJPQA, Volume 11 Issue 3 July 2020 – September 2020 Page 366
21C
holit
ilin®
Cho
line
alfo
scer
ate
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
Clo
sed
Join
t-Sto
ck
Com
pany
Can
onfa
rm
Prod
uctio
n (C
JSC
C
anon
farm
Pr
oduc
tion)
Rus
sia
LSR
-00
5773
/10
06/2
3/20
10--
07/2
5/20
17D
08/2
9/20
19
22C
erep
ro®
Cho
line
alfo
scer
ate
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
Join
t-sto
ck c
ompa
ny
“VER
OPH
AR
M” (
JSC
“V
ERO
PHA
RM
”)R
ussi
aLS
-000
476
06/0
2/20
10-
07/1
5/20
19D
07/1
5/20
19
23C
erep
ro®
Cho
line
alfo
scer
ate
caps
ules
;Jo
int-s
tock
com
pany
“V
ERO
PHA
RM
” (JS
C
“VER
OPH
AR
M”)
Rus
sia
LS-0
0047
505
/31/
2010
-04
/04/
2018
D03
/21/
2019
24C
holit
ilin®
Cho
line
alfo
scer
ate
caps
ules
;
Clo
sed
Join
t-Sto
ck
Com
pany
Can
onfa
rm
Prod
uctio
n (C
JSC
C
anon
farm
Pr
oduc
tion)
Rus
sia
LSR
-00
4850
/10
05/2
8/20
10-
03/0
7/20
19D
03/0
7/20
19
25G
leaz
erC
holin
e al
fosc
erat
e
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
EcoF
arm
Plus
JSC
Rus
sia
LSR
-00
7815
/09
10/0
5/20
09-
06/2
0/20
19D
06/2
0/20
19
26C
eret
on®
Cho
line
alfo
scer
ate
caps
ules
;
Clo
sed
Join
t-Sto
ck
Com
pany
Far
mFi
rma
Sote
ks (C
JSC
Ph
arm
Firm
a So
teks
)
Rus
sia
LSR
-00
5608
/09
07/1
3/20
09-
10.2
1.20
15D
08/1
2/20
19
27M
undi
zal
Cho
line
Salic
ylat
ege
l for
topi
cal
appl
icat
ion;
Mun
difa
rma
gmbH
Ger
man
yP
N01
1976
/ 0
102
/15/
2008
-08
/15/
2014
D08
/25/
2017
28G
liatil
inC
holin
e al
fosc
erat
e
solu
tion
for
intra
veno
us a
nd
intra
mus
cula
r ad
min
istra
tion;
Italfa
rmak
o S.
p.A
.Ita
lyP
N01
1966
/ 0
212
/17/
2007
-02
/20/
2018
D07
/03/
2019
29G
liatil
inC
holin
e al
fosc
erat
eca
psul
es;
Italfa
rmak
o S.
p.A
.Ita
lyP
N01
1966
/ 0
112
/17/
2007
-09
/17/
2019
D09
/17/
2019
Con
t...
Modification of Choline Derivatives and the Study of their Pharmacological Activity
IJPQA, Volume 11 Issue 3 July 2020 – September 2020 Page 367
Arsenic, method I <211>: Proceed as directed in the test for arsenic under choline chloride; the limit is 2 µg per gram.Lead <251>: Proceed as directed in the test for lead under choline chloride; not more than 0.3 µg per gram is found.Heavy metals, method II <231>: 10 µg per gram.Limit of total amines: Proceed as directed in the test for the limit of total amines under choline chloride; not more than 10 µg per gram.Test solution: Transfer 10 grams of choline bitartrate to a beaker containing a plastic-coated stirring bar, add 70 mL of sodium hydroxide TS and 130 mL of water and stir until dissolved.Chromatographic purity: Buffer solution, mobile phase, standard solution, and chromatographic system—Proceed as directed in the test for chromatographic purity under choline chloride.Test solution: Transfer about 500 mg of choline bitartrate, accurately weighed, to a centrifuge tube; add 2 mL of water, and swirl to dissolve. Add 0.5 mL of potassium chloride solution (7.5 in 25), centrifuge, and transfer 1 mL of the supernatant to a 24 mL screw-capped vial. Dry at 120ºC for 2 hours. Add 400 mg of 3,5-dinitrobenzoyl chloride and 10 mL of acetonitrile, and mix. Cap the vial, and heat at 55ºC for 2 hours. Cool to room temperature, add 5 mL of water and allow to stand for 5 minutes. Quantitatively transfer this solution to a 50 mL volumetric flask, dilute with mobile phase to volume, and mix. Pipet 2 mL of the solution to a 25 mL volumetric flask, dilute with mobile phase to volume and mix.Procedure: Separately inject equal volumes (about 20 µL) of the standard solution and the test solution into the chromatograph, record the chromatograms, and measure all the peak responses. Calculate the percentage of each impurity in the portion of choline bitartrate taken by the formula:
(253.25/139.62)62,500(C/W)(ri/rS)Where, 253.25 and 139.62 are the molecular weights of
choline bitartrate and choline chloride, respectively; C is the concentration of USP choline chloride, RS, in mg per mL, in the standard solution; W is the weight, in mg, of choline bitartrate taken to prepare the test solution; ri is the peak response for each impurity, other than that of the choline bitartrate derivative and 3,5-dinitrobenzoic acid; and rS is the peak response for the choline chloride derivative in the standard solution; not more than 0.3% of any individual impurity is found, and not more than 2% of total impurities is found.
Residual solvents <467>: Meets the requirements, except that the limit for 1,4-dioxane is 10 µg per gram.Assay: Transfer about 200 mg of choline bitartrate, accurately weighed, to a conical flask, and dissolve with 50 mL of glacial acetic acid. Titrate with 0.1 N perchloric acid VS, determining the endpoint potentiometrically (see Titrimetry <541>). Perform a blank determination, and make any necessary correction. Each mL of 0.1 N perchloric acid is equivalent to 25.32 mg of C9H19NO7 (Table 1).
USP Choline Chloride Reference Standard
C5H14ClNO 139.62(2-Hydroxyethyl)trimethylammonium chloride.2-Hydroxy-N,N,N,-trimethylethanaminium chloride [67-
48-1].• Choline chloride contains not less than 99 percent and not
more than 100.5 percent of C5H14ClNO, calculated on the anhydrous basis.
IdentificationA: Infrared absorption <196 K>.B: A solution (1 in 20) met Chloride test requirements
<190>.pH <790>: Between 4 and 7 (1 in 10).Water, method I <920>: Less than 0.5%.Residue on ignition <280>: Less than 0.05%.Arsenic, method I <210>: Add 30 mL of water to 5 mL
of hydrochloric acid (HCl) to dissolve the sample: the limit is 2 µg per gram.
Lead <250>: Replace chloroform with methylene chloride to prepare solution of the extract of dithizone extraction and standard dithizone.Ammonium hydroxide-sodium hydroxide solution: Transfer 8.5 grams of sodium hydroxide (NaOH) solution (1 in 2) in a plastic bottle, and add 110 mL of ammonium hydroxide and mix contents.Standard solution: Transfer 1.1 mL of the diluted standard lead solution to a separatory funnel containing 30 mL of water.Test solution: Dissolve 4 grams in a separatory funnel that contains 30 mL of water.Procedure: Add 5 mL of ammonium citrate solution and 3 mL of potassium cyanide solution to standard and test solution. Extract each of the resulting solutions thrice with 6 mL portions of the dithizone extraction solution, shake for 60 seconds, and drain-off each extract into another separator. Add 20 mL of nitric acid (1 in 100) to the combined dithizone solutions and shake for 30 seconds. Discard methylene chloride layer. Add 5 mL of ammonia cyanide solution, 3 mL of ammonium hydroxide-sodium hydroxide solution, and 12 mL of standard dithizone solution. Shake for 50 seconds. Allow the phases to separate. Now, measure the absorbance of the lower layer at 520 nm with a suitable spectrophotometer, found less than 0.4 µg per gram. The absorbance of the test solution is not more than the absorbance of the standard solution.
Heavy metals, method II <231>: 0.001%Limit of total aminesStandard solut ion: Weigh an accurate quant ity of trimethylamine hydrochloride and dissolve the same in water. Dilute quantitatively and stepwise if necessary, in order to obtain a solution with known concentration of 400 µg per mL.
Modification of Choline Derivatives and the Study of their Pharmacological Activity
IJPQA, Volume 11 Issue 3 July 2020 – September 2020 Page 368
Test solution: Transfer 15 grams of choline chloride to a beaker with a plastic-coated stirring bar. To this, add 150 mL of water and 40 mL of sodium hydroxide TS. Stir the contents until dissolved.System suitability solution: Weigh an accurate quantity of trimethylamine hydrochloride and dissolve the same in water. Dilute quantitatively and stepwise if necessary, in order to obtain a solution that contains 15 µg of trimethylamine hydrochloride per mL. Transfer 15 mL of this solution to a beaker containing a plastic-coated stirring bar, add 150 mL of water and 25 mL of sodium hydroxide TS. Stir the contents until they get dissolved.Electrode system: Use an ammonia-specific gas-sensing electrode with internal reference connected to a pH meter which is capable of measuring potentials with a minimum reproducibility of ±0.11 mV (see pH <790>).Standard response line: Transfer 25 mL of sodium hydroxide TS to an appropriate beaker, and add water in the quantity to total a volume of 210 mL. Add a plastic-coated stirring bar, thereafter insert electrode into the solution and record the potential in mV. Continue stirring, and at every interval of 5 minutes, add 0.25, 0.65, 1.5, and 2.5 mL of standard solution. Record the potential after each addition of the standard solution. Plot the logarithms of the cumulative trimethylamine concentrations (0.55, 1.55, 2.55, and 5.5 µg per mL) vs. potential in mV. Now, determine the slope (S) of the standard response line for the electrode.System suitability: Proceed with the system suitability solution as directed for test solution in the procedure, and measure the potentials. The trimethylamine equivalent is found to be between 8.65 and 11.55 mg per liter.Procedure: Rinse the electrode, insert it into the test solution, stir, and record the potential in mV. Add 0.2 mL of the standard solution, and record the potential. Add another 0.2 mL of the standard solution, and record the potential. It may be noted that a third aliquot of 0.3 mL needs to be added if the total change after the second addition of the standard solution is not more than 10 mV. Calculate the quantity, in µg per gram of total amines in the portion of choline chloride taken by the formula:
500VA / (F - 1)WWhere, VA is the total volume of the standard solution
added to the test solution; W is the weight in grams of choline chloride taken to prepare the test solution; and the correction factor, F, is calculated by the formula:
antilog [(mVF - mV0)/S]Where, mVF is the final reading in mV, after addition of
the standard solution; mV0 is the initial reading in mV of the test solution; S is the slope of the standard response line for the electrode. Less than 0.0011% was found.Chromatographic purity
Buffer solution: Dissolve 7.2 grams of anhydrous dibasic sodium phosphate in 1 liter of water. Adjust with phosphoric acid in order to obtain pH 2.5.
Mobile phase: Prepare a filtered and degassed mixture of buffer solution and acetonitrile (70:30).Standard solution: Transfer an accurately weighed amount, less than 150 mg of USP choline chloride RS to a 25 mL screw-capped vial. Add 380 mg of 3,5-dinitrobenzoyl chloride and 12 mL of acetonitrile. Cap the vial, heat to 55ºC, and continue heating for 2 hours. Cool to room temperature (RT), and add 6 mL of water. Allow the mixture to stand for 5 minutes. Now, quantitatively transfer the solution to a 25 mL volumetric flask, dilute with acetonitrile to volume, and mix. Dilute a volume of this solution with the mobile phase in order to obtain a solution that has a known concentration of 3 µg of USP choline chloride RS per mL.Test solution: Transfer about 120 mg of choline chloride, accurately weighed, to a 25 mL screw-capped vial. Dry at 125ºC for 2.2 hours. Add 410 mg of 3,5-dinitrobenzoyl chloride and 12 mL of acetonitrile. Cap the vial, heat it to 55ºC, and then, continue heating it for 2.2 hours. Cool to RT, and add 5.5 mL of water. Allow the mixture to stand for 5 minutes. Now, quantitatively transfer the solution to a 50 mL volumetric flask, dilute with mobile phase to volume, and mix. Pipet 3 mL of the solution to a 25 mL volumetric flask, dilute with mobile phase to volume and mix.Chromatographic system (refer to chromatography <621>): The liquid chromatograph is equipped with a 208 nm detector and a 4.6 mm × 25 cm column, which contains L7 packing. The column temperature is maintained at 30ºC. The flow rate is about 1 mL per minute. The standard solution was chromatographed, and the peak responses were recorded as was directed for the procedure: the capacity factor, k’, is not less than 2, and the relative standard deviation (RSD) determined from the choline chloride derivative peak is not more than 6%.Procedure: Separately inject equal volumes, about 25 µL, of standard and test solution into the chromatograph. Record the chromatograms, and measure all the peak responses. Calculate the percentage of each impurity in the portion of choline chloride taken by the formula:
62,500(C/W)(ri/rS)Where, C is the concentration in mg per mL of USP choline
chloride RS in the standard solution; W is the weight in mg of choline chloride that was taken to prepare the test solution; ri is the peak response for each impurity, other than that for the choline chloride derivative and 3,5-dinitrobenzoic acid obtained from the test solution; and rS is the peak response for the choline chloride derivative obtained from the standard solution. The individual impurity found was less than 0.35% and the total impurity found was less than 2%.Residual solvents <466>: Meets the requirements, except that the limit for 1,4-dioxane is 10 µg per gram.Assay: Transfer an accurately weighed quantity of choline chloride, about 120 mg, to a conical flask, dissolve in 35 mL of water, and add 3 drops of acetic acid. Titrate with 0.1 N silver nitrate VS, determining the endpoint potentiometrically (see Titrimetry <541>). Perform a blank determination, and make
Modification of Choline Derivatives and the Study of their Pharmacological Activity
IJPQA, Volume 11 Issue 3 July 2020 – September 2020 Page 369
any necessary correction. Each mL of 0.1 N silver nitrate is equivalent to 13.96 mg of C5H14ClNO.USP Acetylcholine Chloride Reference Standard
C7H16ClNO2 181.66Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-, chloride. Choline acetate (ester) chloride [60-31-1].• Acetylcholine chloride contains not less than 98 percent
and not more than 102 percent of C7H16ClNO2, calculated on the dried basis.
IdentificationA: Infrared absorption <196 K>.B: Add 5.5 mL of silver nitrate TS to 5.5 mL of solution (1 in 10). A white, curdy precipitate is formed, which is soluble in ammonium hydroxide and insoluble in nitric acid.Melting range, class I <740>: Between 149 and 152ºC.Acidity: Dissolve 110 mg in 12 mL of recently boiled water, and add one drop of bromothymol blue TS immediately. It is observed that less than 0.55 mL of 0.01 N sodium hydroxide produces a color change.Loss on drying <730>: Dry it at 105ºC for 3.5 hours. It lost less than 1.1% of its weight.Residue on ignition <280>: This was less than 0.21%.Chloride content: Transfer accurately weighed 280 mg to a porcelain casserole, and add 140 mL of water and 1 mL of dichlorofluorescein TS. Mix the solution. Now, titrate with 0.1 N silver nitrate VS until silver chloride flocculates and the mixture turns faint pink in color. Each mL of 0.1 N silver nitrate is equivalent to 3.545 mg of chloride (Cl). The quantity of Cl calculated on dried basis was found to be more than 19.355% but less than 19.785%.Assay: Accurately weight 400 mg of acetylcholine chloride, and dissolve in 15 mL of water in conical flask with a glass stopper. Add 41 mL of 0.1 N sodium hydroxide VS, and heat on steam bath for 30 minutes. Insert the glass stopper and allow the mixture to cool. Now, add phenolphthalein TS, and then titrate excess alkali with 0.1 N sulfuric acid VS. A blank determination is performed (refer residual titrations under titrimetry <541>). Each mL of 0.1 N sodium hydroxide is equivalent to 18.17 mg of C7H16ClNO2.
EUROPEAN PHARMACOPEIAAcetylcholine chloride reference standard acetylcholini chloridum C7H16ClNO2 Mr 181.7 [60-31-1], definition 2-(scetyloxy)-N,N,N-trimethylethanaminium chloride. Content: 98.55 to 101.55% (dried substance).IdentificationFirst identification: B, E. Second identification: A, C, D, E.
A. Melting point (2.2.13): This is from 149.1 to 152.2°C. The substance to be examined in put into a capillary tube. It is dried in an oven at about 100 to 106°C for 3.1 hours. Then, the tube is sealed and melting point is determined.
B. Infrared absorption spectrophotometry (2.2.23). Comparison: Acetylcholine chloride CRS.
C. Examine the chromatograms obtained in the test for related substances. The result is that the principal band in the chromatogram obtained with test solution (b) is similar in position, color, and size to the one obtained with reference solution (b).
D. Add 12 mL of dilute sodium hydroxide solution R to 16 mg, and then 2.5 mL of 0.025 M potassium permanganate. Then, heat the contents. By the vapors formed, the color of the litmus paper R gets changes from red to blue.
E. 0.55 mL of solution S (refer tests) gives reaction (a) of chlorides (2.3.2). Test solution S. Dissolve 5.5 grams in carbon dioxide (CO2)-free water R and then, dilute to 55 mL using same solvent.
Appearance of SolutionSolution S is clear (2.2.2) and less intensely colored than the reference solution Y6 or BY6 (2.2.1, method II). AcidityDilute 1.2 mL of solution S to make it 12 mL using CO2-free water R. Add 0.055 mL of phenolphthalein solution R. It was found that color of the indicator got changed to pink with less than 0.45 mL of 0.01 M sodium hydroxide. Related Substances—Thin-Layer Chromatography (2.2.26)The solutions are to be prepared immediately before their use. Test solution (a): 0.35-gram of the substance which is to be examined is dissolved in methanol R. Then the mixture if diluted to 3.5 mL using the same solvent. Test solution (b): Using methanol R, 1.5 mL of the test solution (a) is then diluted to 10.5 mL. Reference solution (a): Using methanol R, 1.5 mL of the test solution (a) is then diluted to 100 mL.Reference solution (b): Using the same solvent, 25 mg of acetylcholine chloride CRS dissolved in methanol R is diluted. Reference solution (c): 0.5 mL of test solution (a) is added to 25 mg of choline chloride R dissolved in methanol R. This solution is further diluted to 2.5 mL using methanol R. Plate: TLC silica gel plate R. Mobile phase: Mix 25 volumes of a 45 g/liter solution of ammonium nitrate R, 25 volumes of methanol R, and 65 volumes of acetonitrile R. Application: 6 µL in the form of bands of 10.5 × 2.5 mm. Development: Over 2/3rd of the plate. Detection: Spray with potassium iodobismuthate solution R3. System suitability: The chromatogram obtained with reference solution (c) shows two clearly separated bands.Limits: Impurity, if any. Other than the principal band, all other bands obtained with the test solution (a) in the chromatogram,
Modification of Choline Derivatives and the Study of their Pharmacological Activity
IJPQA, Volume 11 Issue 3 July 2020 – September 2020 Page 370
are less intense than the principal band obtained with 1% of the reference solution (a) chromatogram.Trimethylamine: Take 15 mL of sodium carbonate solution R and then dissolve 0.12-gram in it. Now, heat the solution to boiling. Litmus paper R did not change its color from blue and no vapors appeared. Heavy metals (2.4.7): The maximum limit is 12 ppm. It is observed that 10 mL of solution S is in compliance with limit test A. The standard solution of lead (Pb) is used to prepare the standard of 1.5 ppm Pb R. Loss on drying (2.2.30): The maximum loss observed is 1%. In order to determine the loss on drying, 1.5 grams was dried in an oven for 3.5 hours at 110°C. Sulfated ash (2.4.13): The maximum sulfated ash that was observed is 0.15%. During the test for loss on drying, the sulfated ash was determined in the residue. Assay: For this, 0.25-gram was dissolved in 25 mL of carbon dioxide-free water R. The solution was then neutralized using 0.01 M sodium hydroxide. 0.16 mL of phenolphthalein solution R was used as an indicator. Then, 25 mL of 0.1 M sodium hydroxide was added. The mixture was allowed to stand for 40 minutes. Thereafter, the mixture was titrated with 0.1 M HCl. It is observed that 1.5 mL of 0.1 M NaOH is equivalent to 18.29 mg of C7H16ClNO2.
RUSSIAN PHARMACOPIEAAcetylcholine chloride [60-31-1]. С7Н16СlNО2. (M.M. 181.66). N-[2-(acetyloxy) ethyl] -N, N, N-trimethylammonium chloride. It is in the form of crystalline powder. It can be easily dissolved in cold water, as well as, 96% alcohol. It is practically insoluble in ether. It decomposes in hot water and alkali solutions. It is to be stored at a temperature of -20ºС.Pharmaceutical Analysis for Choline Ester DerivativesA high-performance liquid chromatography (HPLC)/ electrospray ionization mass spectrometry (EIMS) is used to detect choline and ACh in a pharmaceutical preparation. In pharmaceutical preparations that contain choline esters, it is important to use certain detective methods for choline or acetylcholine in these preparations.
ACh and choline detection using ultra-violet (UV) is extremely difficult since strongly UV chromophore, which strongly absorb, are absent in the molecule(s).65-67 That is why there are other methods are suggested which include electrochemical,68-72 or spectrophotometric detection,73 since in both these methods, prior enzymatic reaction is required, and various other methods that involve materials, which are labelled radioisotopically.74-76 The first method for ACh detection was done by the use of mass spectroscopy with gas chromatography. This method is specially used for quaternary ammonium species. It is observed that there is significant improvement over the methods which were earlier available, e.g., bioassay.77
However, this approach is still not direct. The reason being that it requires the conversion of quaternary ammonium species to volatile tertiary amine through demethylation reaction, and this reaction could be achieved chemically78 or through
pyrolysis.79 Ionization methods, like, thermo spray ionization80
and fast-atom bombardment81 were immediately put to use for the analysis of ACh and other related compounds,82,83 since they enabled the combination of online HPLC separations using highly sensitive mode of mass spectrometric detection. Further, no pre-treatment of non-volatile or thermally fragile analytes was required in these ionization methods. A lot of renovations were done to introduce a new method which is called electro spray ionization (ESI).84 This method is better than other methods when it used with mass spectroscopy to detect ACh and with a separation method like HPLC.64
Another study used refractive index due to the absence of UV chromophore, but the disadvantage of this method that it is not suitable for the detection of low levels ACh that come up against when it is needed to make analysis to ensure the presence of this neurotransmitter in certain matrices, like cerebrospinal fluids. Some new methods are used to change ACh to hydrogen peroxide following electrochemical detection, but this method offers a low detection limit.
It has been confirmed that ACh can be detected by the use of certain reagents, like alkyl sulfonate, which is considered as an ion-pairing agent for HPLC,85-89 other methods, like mass spectroscopy, are also used for ACh detection,82,84,90-94 but it is important to know that this method requires a volatile phase.
CONCLUSIONAccording to the previous studies which had been done for the modification of choline esters and their uses nowadays as drugs for the treatment of many diseases, this gave us the inspiration to look forward to further modifications of choline esters, which will have the same effect as ACh with higher activity and efficacy. So our study is relevant at the present time and will be expected as a significant breakthrough in science.
ACKNOWLEDGEMENT The authors acknowledge that the RUDN University Program 5-100 supported the preparation of this article.
REFERENCES 1. Dale, H. H.: J. Pharmacol. Exp. Ther. 6:147, 1914.2. Loewi, O.: Arch. Gesamte. Physiol. (Pfluegers) 189:239,1921.3. Zola-Morgan, S., and Squire, L. R.: Annu. Rev. Neurosci. 16:547,
1994.4. Frank, H. S., and Wen, W.-Y.: Discuss. Faraday Soc. 24:133, 1957.5. Hille, B.: Annu. Rev. Physiol. 38:139, 1976.6. Karlin, A.: In Cotman, C. U., Poste, G., and Nicolson, G. L. (eds.).
Cell Surface and Neuronal Function. Amsterdam, Elsevier Biomedical, 1980, p. 191.
7. Changeaux, J. P., Devillers-Thiery, A., and Chermoulli, P.: Science 225:1335, 1981
8. Anholt, R., et al.: In Martonosi, A. N. (ed.). The Enzymes of Biological Membranes, vol. 3. New York, Plenum Press, 1985.
9. Raftery, M. A., et al.: Science 208:1445, 1980.10. Sargent, P. B.: Neuroscience 16:403, 1994.11. Dani, J. A.: Biol. Psychiatry 49:166, 2001.12. Rattray, M.: Biol. Psychiatry 49:185, 2001.13. Goyal, R. K.: N. Engl. J. Med. 321:1022, 1989.
Modification of Choline Derivatives and the Study of their Pharmacological Activity
IJPQA, Volume 11 Issue 3 July 2020 – September 2020 Page 371
14. Birdsall, N. J. M., et al.: Pharmacology 37(Suppl.):22, 1988.15. Mutschlur, E., et al.: Prog. Pharmacol. Clin. Pharmacol. 7:13,
1989.16. Doods, H. N., et al.: Prog. Pharmacol. Clin. Pharmacol. 7:47,1989.17. Barnes, P. J.: Life Sci. 52:521, 1993.18. Rubanyi, G. M.: J. Cell Biol. 46:27, 1991. 19. Kilbinger, H., Dietricht, C., and von Bardeleben, R. S.: J. Physiol.
Paris 87:77, 1993.20. Linder, M. E., and Gilman, A. E.: Sci. Am. 27:56, 1992.21. Caufield, M. P.: Pharmacol. Ther. 58:319, 1993.22. Berridge, M. J., and Irvine, R. F.: Nature 312:315, 1984.23. Berridge, M. J.: Annu. Rev. Biochem. 56:159, 1987.24. Clapham, D. E.: Annu. Rev. Neurosci. 17:441, 1994.25. Haga, T., and Nada, H.: Biochim. Biophys. Acta. 291:564,1973.26. Cavallito, C. J., et al.: J. Med. Chem. 12:134, 1969.27. Aquilonius, S. M., et al.: Acta Pharmacol. Toxicol. 30:129,1979.28. Whittaker, V. P.: Trends Pharmacol. Sci. 7:312, 1986.29. Namba, T., and Grob, D.: J. Neurochem. 15:1445, 1968.30. Partington, P., Feeney, J., and Burgen, A. S. V.: mol. Pharmacol.
8:269, 1972.31. Casey, A. F.: Prog. Med. Chem. 11:1, 1975 51. Ordentlich,
A., et al.: J. Biol. Chem. 268:17083, 1993 32. Behling, R. W., et al.: Proc. Natl. Acad. Sci. U. S. A. 85:6721, 1988.
32. Nordvall, G., and Hacksell, U.: J. Med. Chem. 36:967, 1993.33. Martyn JAJ, Fagerlung MJ, Eriksson LI. Basic principles of
neuro-muscular transmission. Anaesthesia. 2009;64(suppl 1):1–9.34. Quinn DM. Acetylcholinesterase: enzyme structure, reaction
dynamics, and virtual transition states. Chem Rev. 1987; 87:955–975.
35. G re e nbla t t H M, D v i r H , Si l m a n I , Su s sm a n J L . Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer’s disease. JMol Neurosci. 2003; 20:369–384.
36. Nachmansohn D, Wilson IB. The enzymic hydrolysis and synthesis of acetylcholine. Adv. Enzymol. 1951; 12:259–339.
37. Rosenberry TL. Acetylcholinesterase. Adv Enzymol. 1975; 43:103–218.
38. Changeux J-P. Allosteric receptors: from electric organ to cognition. Ann Rev Pharmacol Toxicol. 2010;50:1–38.
39. Picciotto MR, Higley MJ, mineur YS. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron. 2012;76:116–129.
40. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science. 1973;180:871–872.
41. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116:2843–2854.
42. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron. 2000;28:325–334.
43. Adams CE, Stevens KE. Evidence for a role of nicotinic acetylcholine receptors in schizophrenia. Front Biosci. 2007;12:4755–4772.
44. Herrero JL, Roberts MJ, Delicato LS, Gieselmann MA, dayan P, Thiele A. Acetylcholine contributes through muscarinic receptors to attentional modulation in V1. Nature. 2008;454:1110–1114.
45. Pinto L, Goard MJ, Estandian D, Xu M, Kwan AC, Lee SH, Harrison TC, Feng G, Dan Y. Fast modulation of visual perception by basal forebrain cholinergic neurons. Nat Neurosci. 2013;16:1857–1863.The authors show that optogenetic stimulation of ACh release in the mouse visual cortex improves perception on a trial-by-trial basis.
46. Food and Nutrition Board. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Panthotenic Acid, Biotin, and Cholin; National Academy Press: Washington, DC, USA, 1998.
47. Patterson, K.Y.; Bhagwat, A.S.; Williams, J.R.; Howe, J.C.; Holden, J.M.; Zeisel, S.H.; Da Costa, C.A.; Mar, H. USDA Database for the Choline Content of Common Foods. Release Two. Available online: http://www.ars.usda.gov/Services/docs.htm?docid=6232 (accessed on 26 August 2017).
48. Garner, S.C.; Mar, M.H.; Zeisel, S.H. Choline distribution and metabolism in pregnant rats and fetuses are influenced by the choline content of the maternal diet. J. Nutr. 1995, 125, 2851–2858.
49. Holmes-McNary, M.Q.; Cheng, W.L.; Mar, M.H.; Fussell, S.; Zeisel, S.H. Choline and choline esters in human and rat milk and in infant formulas. Am. J. Clin. Nutr. 1996, 64, 572–576.
50. Zeisel, S.H.; Char, D.; Sheard, N.F. Choline, phosphatidylcholine and sphingomyelin in human and bovine milk and infant formulas. J. Nutr. 1986, 116, 50–58.
51. Zeisel, S.H.; Da Costa, K.-A.; Franklin, P.D.; Alexander, E.A.; Lamont, J.T.; Sheard, N.F.; Beiser, A. Choline, an essential nutrient for humans. FASEB J. 1991, 5, 2093–2098.
52. Da Costa, K.A.; Badea, M.; Fischer, L.M.; Zeisel, S.H. Elevated serum creatine phosphokinase in choline-deficient humans: Mechanistic studies in C2C12 mouse myoblasts. Am. J. Clin. Nutr. 2004, 80, 163–170.
53. Da Costa, K.A.; Niculescu, M.D.; Craciunescu, C.N.; Fischer, L.M.; Zeisel, S.H. Choline deficiency increases lymphocyte apoptosis and DNA damage in humans. Am. J. Clin. Nutr. 2006, 84, 88–94.
54. Xu, X.; Gammon, M.D.; Zeisel, S.H.; Lee, Y.L.;Wetmur, J.G.; Teitelbaum, S.L.; Bradshaw, P.T.; Neugut, A.I.; Santella, R.M.; Chen, J. Choline metabolism and risk of breast cancer in a population-based study. FASEB J. 2008, 22, 2045–2052.
55. Ibiebele, T.I.; Hughes, M.C.; Pandeya, N.; Zhao, Z.; Montgomery, G.; Hayward, N.; Green, A.C.; Whiteman, D.C.; Webb, P.M. High intake of folate from food sources is associated with reduced risk of esophageal cancer in an Australian population. J. Nutr. 2011, 141, 274–283.
56. Ying, J.; Rahbar,M.H.; Hallman, D.M.; Hernandez, L.M.; Spitz,M.R.; Forman,M.R.; Gorlova, O.Y. Associations between dietary intake of choline and betaine and lung cancer risk. PLoS ONE 2013, 8, e54561.
57. Zhang, C.X.; Pan, M.X.; Li, B.; Wang, L.; Mo, X.F.; Chen, Y.M.; Lin, F.Y.; Ho, S.C. Choline and betaine intake is inversely associated with breast cancer risk: A two-stage case-control study in China. Cancer Sci. 2013, 104, 250–258.
58. Zhou, R.F.; Chen, X.L.; Zhou, Z.G.; Zhang, Y.J.; Lan, Q.Y.; Liao, G.C.; Chen, Y.M.; Zhu, H.L. Higher dietary intakes of choline and betaine are associated with a lower risk of primary liver cancer: A case-control study. Sci. Rep. 2017, 7, 679.
59. Zeisel SH. 1981. Dietary choline: bio-chemistry, physiology, and pharmacology. Annu. Rev. Nutr. I: 95-121.
60. Zeisel SH. 1990. Biological conse quences of choline deficiency. In Choline Metabolism and Brain Function, ed.Biochim. R Wurtman, J Wurtman, pp. 75-99. New York: Raven.
61. Zeisel SH. 1993. Choline. In Modem Zeisel SH. 1988. Rat and human mam- Nutrition in Health and Disease, ed. ME Shils, JA Olson, M Shike, pp. 449-58. Philadelphia: Lea and Febiger.
Modification of Choline Derivatives and the Study of their Pharmacological Activity
IJPQA, Volume 11 Issue 3 July 2020 – September 2020 Page 372
62. William Garner, Margaret Garner, George minno, David Gooden. Patent Application Publication. Pub. No.: US 2014/0121266 A1. May 1, 2014.
63. Jose Alexander; JosepH A. Fix, both of Lawrence, Kans. Assignee: Merck and Co., Inc., Rahway, N. Patent Number: 4,729,989. 45 Date of Patent: ‘Mar. 8, 1988J.
64. REYES, Michael Ray; c/o HALO LIFE SCIENCE, LLC, 122 Creekside Drive, Victoria, Texas 77904 (US). CABRERA, Robert; c/o HALO LIFE TR), SCIENCE, LLC, 122 Creekside Drive, Victoria, Texas). 77904 (US).
65. F.T. Tao, J.S. Thurber, D.M. Dye, J. Pharm. Sci. 73 (1984) 1311_/1313.
66. F.W. Newell, J.T. Ernest, Ophthalmology: Principles and Concepts, 3rd ed., C.V. Mosby Co., St. Louis, MO, 1974, pp. 97_/101.
67. T.-H. Tsai, J. Chromatogr. B 747 (2000) 111_/122.68. P.E. Potter, J.L. Meek, N.H. Neff, J. Neurochem. 41 (1983)
188_/194.69. G. Damsma, D. Lammerts van Bueren, B.H.C. Westerink, A.S.
Horn, Chromatographia 24 (1987) 827_/831.70. J. Chen, X.-Q. Lin, Z.-H. Chen, S.-G. Wu, S.-Q. Wang, Anal.
Lett. 34 (2001) 491_/501.71. Guerrieri, F. Palmisano, Anal. Chem. 73 (2001) 2875_/2882.72. Curulli, S. Dragulescu, C. Cremisini, G. Palleschi, Electroanalysis
13 (2001) 236_/242.73. J. Ricny, S. Tucek, I. Vins, J. Neurosci. Meth. 41 (1992) 11_/17.74. K. Kawashima, H. Ishikawa, M. Mochizuki, J. Pharmacol. Meth.
3 (1980) 115_/123.75. P.A. Shea, M.H. Aprison, Anal. Biochem. 56 (1973) 165_/177.76. J.K. Saelens, W.R. Stoll, J. Pharmacol. Exp. Ther. 147 (1965)
336_/340.77. V.P. Whittaker, M.N. Sheridan, J. Neurochem. 12 (1963)
363_/369.
78. D.J. Jenden, M.A. Roch, K. Booth, Anal. Biochem. 55 (1973) 438_/448.
79. W.B. Stavinoha, S.T. Weintraub, Anal. Chem. 46 (1974) 757_/760.80. M.L. Vestal, Int. J. Mass Spectrom. Ion Phys. 46 (1983) 193_/196.81. R.M. Caprioli, T. Fan, J.S. Cottrell, Anal. Chem. 58(1986)
2949_/2954.82. D.J. Liberato, A.L. Yergey, S.T. Weintraub, Biomed. Environ.
Mass Spectrom. 13 (1986) 171_/174.83. H. Ishimaru, Y. Ikarashi, Y. Maruyama, Biol. Mass Spectrom.
22 (1993) 681_/686 Spectrom. 22 (1993) 681_/686.84. L.D. Acevedo, Y. Xu, X. Zhang, R.J. Xin, Pearce, A. Yergey, J.
Mass Spectrom. 31 (1996) 1399_/1402.85. F.T. Tao, J.S. Thurber, D.M. Dye, J. Pharm. Sci. 73 (1984)
1311_/1313.86. J. Gorham, J. Chromatogr. 362 (1986) 243_/253.87. A.W. Teelken, H.F. Schuring, W.B. Trieling, G. Damsma, J.
Chromatogr. 529 (1990) 408_/416.88. E. Haen, H. Hagenmaier, J. Remien, J. Chromatogr. 537 (1991)
514_/519.89. T. Zelles, L. Chernaeva, M. Bayanyi, Z. Deri, V. Adam- Vizi,
E.S. Vizi, J. Neurosci. Res. 42 (1995) 242_/251.90. D.J. Liberato, A.L. Yergey, S.T. Weintraub, Biomed. Environ.
Mass Spectrom L.D. Acevedo, Y. Xu, X. Zhang, R.J. Xin, Pearce, A. Yergey, J. Mass Spectrom. 31 (1996) 1399_/1402.
91. T.A. Getek, M.L. Vestal, T.G. Alexander, J. Chromatogr. 554 (1991) 191_/203.
92. A.L.L. Duchateau, B.H.M. Munsters, G.T.C. Kwakkenbos, R.G.J. Van Leuken, J. Chromatogr. 552 (1991) 605_/612.
93. http://www.pharmacopeia.cn/usp.asp .94. http://www.fptl.ru/biblioteka/farmacop/EP-7.0-2.pdf.95. h t t p: // r e sou rce . r ucm L. r u /fem L/pha r ma copia /14_1/
HTML/1440/index.htmL#zoom=z.
Recommended